Skip to main content
Drug Design, Development and Therapy logoLink to Drug Design, Development and Therapy
. 2026 Nov 4;20:646469. doi: 10.2147/DDDT.S646469

Real-World Twelve-Month Outcomes of Switching from Aflibercept to Faricimab in Chinese Neovascular Age-Related Macular Degeneration with Inadequate Aflibercept Response

Jing Wang 1,*, Fengjiao Li 1,*, Yalin Wang 1, Xianxian Kong 1, Weiyan Zhou 1,✉
PMCID: PMC13744686  PMID: 43001148

Abstract

Purpose

To evaluate 12-month outcomes of switching to faricimab in eyes with neovascular age-related macular degeneration (nAMD) in Chinese patients showing inadequate response to aflibercept, and explore correlations between dynamic changes in subretinal hyperreflective material (SHRM) height, treatment interval and visual prognosis.

Methods

This single-center retrospective cohort included 34 nAMD eyes that had received at least three consecutive aflibercept injections at 4-week intervals. Patients followed a 1+pro re nata (PRN) regimen for 12 months post-switch. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, and the prevalence of subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal hemorrhage (SRH) were evaluated. In 13 eyes with baseline SHRM, generalized estimating equations (GEE) were utilized to explore the association of dynamic SHRM height changes and treatment interval adjustments with visual acuity changes.

Results

A total of 34 eyes were included. CMT dropped significantly after the initial faricimab injection (P = 0.0427). SRF prevalence declined markedly at 6 months, with significant PED and IRF prevalence reductions at 12 months. Among the 11 eyes with baseline SRH, the maximum SRH diameter decreased significantly at month 12 (adjusted P = 0.0039). No significant change was detected in BCVA. Median treatment intervals lengthened from 4.5 to 8.0 weeks (P = 0.017). In 13 eyes with baseline SHRM, SHRM reduction was associated with contemporaneous treatment-interval prolongation (B = −3.299 weeks per 100-μm increase; P < 0.001), but not with subsequent injection intervals or concurrent visual-acuity changes.

Conclusion

Switching to faricimab was associated with overall anatomical improvements and prolonged treatment intervals among pretreated nAMD eyes, while visual gains remained limited. However, complete anatomical resolution was not achieved in all patients. Dynamic changes in SHRM height may represent an exploratory imaging feature associated with treatment interval changes, however, its prospective predictive value and clinical utility remain to be validated.

Keywords: neovascular age-related macular degeneration, faricimab, aflibercept, subretinal hyperreflective material, real-world study

Introduction

Age-related macular degeneration(AMD) is the leading cause of irreversible vision impairment in the elderly worldwide.1 Neovascular age-related macular degeneration (nAMD) is a type of advanced AMD characterized by abnormal neovascularization in the macular region and loss of central vision due to leaky bleeding, accounting for the majority of AMD-related blindness cases.2 Aging is the biggest risk factor, and in China, the number of people with AMD is expected to be 55.19 million by 2050.3 Therefore, optimizing the treatment strategies and methods for nAMD patients in China is of significant importance.

Anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line treatment for nAMD. Aflibercept is one of the most widely used anti-VEGF agents, acting as a decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor (PlGF) to inhibit pathological angiogenesis and vascular leakage.4,5 However, despite its established efficacy, long-term management of nAMD remains challenging due to incomplete treatment response, recurrent disease activity, and unsatisfactory long-term visual outcomes.6,7 Furthermore, frequent intravitreal injections and regular monitoring impose substantial economic and psychological burdens on patients, potentially affecting treatment adherence and visual prognosis.8 Therefore, reducing injection frequency and extending treatment intervals while maintaining anatomical and functional outcomes are important goals in the long-term management of nAMD, as these may alleviate patients’ financial burden, improve treatment adherence, and enhance their confidence in long-term disease management, representing desirable outcomes for both patients and clinicians.

Faricimab is a humanized bispecific antibody that simultaneously targets VEGF-A and angiopoietin-2 (Ang-2), thereby inhibiting pathological neovascularization and promoting vascular stability.9,10 The global Phase III TENAYA and LUCERNE trials demonstrated that faricimab, administered at intervals of up to 16 weeks, achieved noninferior visual outcomes compared with aflibercept administered every 8 weeks, suggesting its potential to extend treatment intervals and reduce treatment burden in patients with nAMD.11,12

Currently, there is no universally accepted definition of inadequate response to anti-VEGF therapy in nAMD, and existing clinical guidelines do not provide standardized diagnostic criteria. Previous studies have commonly considered persistent or recurrent subretinal fluid (SRF) and/or intraretinal fluid (IRF) on optical coherence tomography (OCT) as indicators of an inadequate anatomical response to anti-VEGF treatment.13–15 In the present study, inadequate response to aflibercept was defined as the presence of persistent or recurrent SRF and/or IRF on OCT at the time of switching, despite having received at least three consecutive monthly loading injections of aflibercept before switching, indicating incomplete anatomical control of exudative disease activity.

OCT is an essential tool for diagnosing and assessing the prognosis of nAMD. It can clearly display anatomical landmarks associated with nAMD, such as SRF, IRF, subretinal hyperreflective material (SHRM), and pigment epithelial detachment (PED).16 Among them, SHRM is considered a key anatomical prognostic biomarker. The CATT study noted that SHRM persisted in more than half of the eyes during anti-VEGF therapy.17 Several studies have shown that the presence, volume changes, and morphological characteristics of SHRM are closely related to visual prognosis in patients with nAMD.16,18–21 Beyond its established prognostic value for visual outcomes, SHRM may also reflect neovascular disease activity and response to anti-VEGF therapy.17 Previous studies have suggested that reductions in SHRM thickness following anti-VEGF treatment may partly reflect a decrease in its exudative component.22 Given that OCT-based assessment of disease activity is central to retreatment decisions in nAMD, changes in SHRM height might also be associated with variations in injection intervals.23

However, evidence regarding the real-world outcomes of switching from aflibercept to faricimab in Chinese patients with nAMD who have an inadequate response to aflibercept remains limited. Furthermore, the relationship between longitudinal changes in SHRM height and treatment intervals following the switch to faricimab has not been well characterized in this patient population. Exploring this association may provide additional insights into the potential role of SHRM as an imaging biomarker for individualized anti-VEGF treatment management.

Based on this, this study intends to employ a real-world consecutive cohort design, focusing on anatomical remodeling and visual acuity gains over 12 months following treatment switching to faricimab in Chinese nAMD patients with inadequate response to aflibercept, and investigate the association between SHRM height dynamics and treatment intervals, thereby providing evidence-based insights for individualized clinical decision-making.

Methods

Ethics Statement

This retrospective observational study was reviewed and approved by the Ethics Committee for Biomedical Research Involving Human Subjects of Shandong Provincial Hospital, ethical approval SWYX:NO.2025–156. All data were extracted from the hospital’s electronic medical record system. Informed consent was waived because all data were retrospective and anonymized. Patient identifiers were de-identified according to standard procedures. The study design adhered to the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines, ensuring that the anticipated scientific value outweighed the potential risks.

Participants

This retrospective, single-center, real-world study included 34 eyes of 34 patients with nAMD who had previously received multiple anti-VEGF injections with inadequate treatment response. Patients were identified through the electronic medical records of the Department of Ophthalmology at Shandong Provincial Hospital. Enrollment and follow-up of all patients were conducted from May 2024 to November 2025. A total of 40 eyes were initially screened for eligibility. Of these, 4 eyes were excluded because they did not meet the predefined inclusion and exclusion criteria, and 2 eyes were lost to follow-up. Consequently, 34 patients (34 eyes) were included in the final analysis (Figure 1).

Figure 1.

A flowchart of eye screening, exclusions and final analysis counts.

The patient flow diagram.

The inclusion criteria were as follows: The inclusion criteria were as follows: (1) a diagnosis of nAMD confirmed by clinical examination and multimodal imaging; (2) inadequate response to aflibercept, defined as persistent or recurrent SRF and/or IRF on OCT at the time of switching despite at least three consecutive monthly loading injections of aflibercept; (3) completion of 12 months of follow-up after switching therapy. The exclusion criteria were as follows: (1) macular neovascularization (MNV) secondary to causes other than nAMD, such as high myopia, trauma, angioid streaks, or central serous chorioretinopathy; (2) ocular comorbidities affecting macular morphology, including diabetic maculopathy, retinal vein occlusion, or vitreomacular interface disorders; (3) a history of ophthalmic interventions, including vitrectomy or photodynamic therapy; and (4) non-gradable OCT images at any follow-up visit due to motion/blink artifacts or poor focus preventing reliable assessment of OCT parameters.

Interventions

Before switching, all patients had received at least three intravitreal aflibercept injections. All eyes included had received intravitreal aflibercept every 4 weeks for three consecutive loading injections before switching to faricimab. Patients were considered to have an inadequate response to aflibercept if persistent or recurrent SRF and/or IRF was present on OCT at the time of switching, despite having received at least three consecutive monthly loading injections of aflibercept. The first intravitreal faricimab injection was administered 1 month after the last aflibercept injection. Thereafter, patients were managed with a 1 + pro re nata (PRN) regimen. Under the 1 + PRN regimen, all patients were scheduled for routine clinical follow-up every 4 weeks after the initial faricimab injection. At each follow-up visit, BCVA and OCT findings were assessed. Retreatment was administered only when predefined active progressive disease was identified. Eyes with stable residual SRF or IRF, without visual decline and without increased CMT or PED height, were monitored without reinjection.

Retreatment was performed when disease activity was identified based on any of the following criteria: (1) a decline in best-corrected visual acuity (BCVA) of at least 5 ETDRS letters (or 0.1 logMAR); (2) new-onset or worsening SRF or IRF on OCT; or (3) an increase in CMT or PED compared with the previous visit. All patients were followed for 12 months from the first faricimab injection.

Data Collection

All patients underwent comprehensive ophthalmic examinations before and after switching, including BCVA, non-contact tonometry, fundus photography, and spectral-domain optical coherence tomography (SD-OCT). BCVA was converted to logarithm of the minimum angle of resolution (logMAR) units for statistical analysis. SD-OCT imaging was performed using the Spectralis system (Heidelberg Engineering GmbH). At each visit,a high-definition horizontal fovea-centered line scan (30 ART frames) and a macular raster scan (49 B-scans, 120 μm spacing, covering a 20° × 20° area) were acquired. Mean CMT was automatically calculated using the built-in thickness map within a 0.5-mm radius centered on the fovea. SHRM and PED heights were measured using the device caliper. SHRM height was defined as the distance from the inner border of SHRM to the inner border of the retinal pigment epithelium (RPE), while PED height was measured at the point of maximal separation between the RPE and Bruch’s membrane. The presence of SRF and IRF was also assessed. Subretinal hemorrhage (SRH) was assessed using OCT and color fundus photography. The maximum SRH diameter was measured using ImageJ and expressed in disc diameters (DD), normalized to the vertical optic disc diameter. Two masked retinal graders performed the quality assessment independently; disagreements were adjudicated by a senior retinal specialist. All follow-up SD-OCT images were registered and aligned with the baseline scans.

Primary and Secondary Outcomes

The primary outcomes were changes in BCVA, OCT parameters, and injection intervals. OCT parameters included CMT, PED, SRH and the presence of SRF and IRF, which were assessed at predefined time points after the initial faricimab injection. Injection intervals before and after switching were also compared as a primary outcome. The secondary outcome was the exploratory association between changes in SHRM and injection intervals.

Statistical Analysis

Baseline characteristics and pre-switch clinical parameters were summarized descriptively (Table 1). Decimal BCVA was converted to logMAR for analysis. Repeatedly measured continuous variables, including BCVA, CMT, and PED height, were analyzed using repeated-measures ANOVA (RM-ANOVA), with Greenhouse–Geisser correction and Bonferroni adjustment as appropriate. Linear mixed-effects model (LMM) was also used for sensitivity analyses.

Table 1.

Baseline Demographic and Clinical Characteristics of Patients

Eye (patients), n 34 (34)
Age (years), mean (SD) 67.4 (9.8)
Male gender, n (%) 21 (61.8%)
left eye, n (%) 17 (50.0%)
BCVA (logMAR), mean (SD) 0.60 (0.54)
presence of SRF, n (%) 28 (82.4%)
presence of IRF, n (%)
presence of SRH, n (%)
18 (52.9%)
11 (32.4%)
presence of SHRM, n (%) 13 (38.2%)
PED height (μm), mean (SD) 275.38 (150.69)
CMT (μm), mean (SD) 292.85 (117.80)
Pre-switch injections 4.10 (0.60)

Temporal changes in the proportions of eyes with SRF and IRF in the overall cohort were analyzed using Cochran’s Q test, followed by pairwise comparisons with McNemar’s test after Bonferroni correction. Maximum SRH diameter was analyzed using the Friedman test, followed by exact Wilcoxon signed-rank tests with Bonferroni correction.

Injection intervals were summarized as the median of consecutive injection intervals for each eye, excluding the interval between the last aflibercept and first faricimab injections. Paired differences were assessed using the Wilcoxon signed-rank test and visualized using a paired dot plot. Among eyes with SHRM at baseline, generalized estimating equations (GEE) were used to assess the associations between changes in SHRM height and changes in treatment intervals and logMAR BCVA. Additional sensitivity analyses were performed to assess the robustness and temporal relationships of these associations.

Interobserver reproducibility of manual OCT measurements was evaluated using the intraclass correlation coefficient (ICC) with 95% confidence intervals. All statistical analyses were performed using SPSS version 27.0, and figures were generated using GraphPad Prism. A p value < 0.05 was considered statistically significant.

Results

Baseline Demographic Characteristics

A total of 34 eyes from 34 patients were included in the analysis. Baseline demographic and clinical characteristics are summarized in Table 1. The mean age of the patients was 67.4 ± 9.8 years, and 61.8% were male. There was no statistically significant difference in age between male and female patients (P = 0.691). Before switching to faricimab, patients received intravitreal aflibercept 2mg injections according to 3+PRN regimen. The mean number of pre-switch aflibercept injections was 4.1 ± 0.6 (range, 3–5), with a treatment duration ranging from 3 to 6 months.

At baseline, prior to the first faricimab injection, the mean BCVA was 0.60 ± 0.54 logMAR, the mean CMT was 292.85 ± 117.80 μm, and the mean PED height was 275.38 ± 150.69 μm. SRH was present in 11 eyes (32.4%), with a median maximum diameter of 0.65 DD (IQR, 0.45–1.66). SHRM was present in 13 eyes (38.2%) of eyes, SRF in 28 eyes (82.4%), IRF in 18 eyes (52.9%). At the time of switching, persistent or recurrent exudative activity was observed as isolated SRF in 16 eyes (47.1%), isolated IRF in 6 eyes (17.6%), and concurrent SRF and IRF in 12 eyes (35.3%).

Primary Outcomes: Overall Therapeutic Outcomes After Switching

Visual and anatomical outcomes at baseline and at each follow-up time point after switching from aflibercept to faricimab are summarized in Table 2.

Table 2.

Changes in Visual and Anatomical Outcomes Before and After Switching from Aflibercept to Faricimab

Variables Treatment-naive Baseline 1M Post-Switch 3M Post-Switch 6M Post-Switch 12M Post-Switch P-value
BCVA (logMAR) 0.62 ± 0.58 0.60 ± 0.54 0.50 ± 0.44 0.50 ± 0.43 0.48 ± 0.42 0.44 ± 0.41 0.065
CMT (μm) 312.06 ± 127.75 292.85 ± 117.80 255.09 ± 88.44 264.15 ± 92.46 253.18 ± 89.22 237.26 ± 72.22 <0.001
PED height (μm) 272.71 ± 147.21 275.38 ± 150.69 234.33 ± 147.77 210.04 ± 152.88 206.88 ± 169.06 186.54 ± 153.64 0.012
Maximum SRH diameter (DD) 0.70 (0.27–1.70) 0.65 (0.45–1.66) 0.56 (0.14–1.13) 0.55 (0.12–0.99) 0.32 (0.00–0.71) 0.00 (0.00–0.48) <0.001
SHRM (%) 8(23.5%) 13 (38.2%) 7 (20.6%) 7 (20.6%) 6 (17.6%) 5 (14.7%) <0.001
SRF (%) 30 (88.2%) 28 (82.4%) 22 (64.7%) 21 (61.8%) 18 (52.9%) 17 (50.0%) <0.001
IRF (%) 21 (61.8%) 18 (52.9%) 14 (41.2%) 14 (41.2%) 13 (38.2%) 8 (23.5%) 0.004

Notes: BCVA, CMT, and PED height are presented as mean ± standard deviation (SD) and were analyzed using repeated-measures analysis of variance (RM-ANOVA). Greenhouse–Geisser correction was applied when the sphericity assumption was violated. Maximum SRH diameter is presented as median (interquartile range [IQR]) and was analyzed using the Friedman test. The proportions of eyes with SHRM, SRF, and IRF were analyzed using Cochran’s Q test. All P values represent overall comparisons across time points.

Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; PED, pigment epithelial detachment; SRH, subretinal hemorrhage; SHRM, subretinal hyperreflective material; SRF, subretinal fluid; IRF, intraretinal fluid.

Assumption assessments indicated deviations from normality and/or violations of sphericity among the repeated measurements of BCVA, CMT, and PED height (Supplementary Table S1). Greenhouse–Geisser correction was applied where sphericity was violated. Given these assumption violations, the RM-ANOVA results were interpreted cautiously, and linear mixed-effects models were additionally used to assess the robustness of the findings.

Figure 2a shows the changes in mean BCVA (logMAR) at different time points after switching to faricimab. Compared with baseline, the mean BCVA numerically improved from 0.60 ± 0.54 logMAR to 0.50 ± 0.44 logMAR after the first injection. At 3, 6, and 12 months after treatment, the mean BCVA further improved to 0.50 ± 0.43, 0.48 ± 0.42, and 0.44 ± 0.41 logMAR, respectively. Although a numerical improvement in BCVA was observed, the overall change did not reach statistical significance in the primary RM-ANOVA after Greenhouse–Geisser correction (P = 0.065).

Figure 2.

Three line graphs showing mean BCVA, central macular thickness and PED height across time points. A) Line graph of Mean BCVA across time points with vertical error bars. X-axis label: Treatment-naive, Baseline, 1M post-switch, 3M post-switch, 6M post-switch, 12M post-switch. Y-axis label: Mean BCVA (logMAR). Y-axis range: 0.0 to 1.5. One line series with circular markers. Plotted mean points (x, y): Treatment-naive: 0.60, Baseline: 0.58, 1M post-switch: 0.50, 3M post-switch: 0.50, 6M post-switch: 0.49, 12M post-switch: 0.44. B) Line graph of Central Macular Thickness across time points with vertical error bars and two bracket annotations above the plot. X-axis label: Treatment-naive, Baseline, 1M post-switch, 3M post-switch, 6M post-switch, 12M post-switch. Y-axis label: Central Macular Thickness (micrometer). Y-axis range: 0 to 500. One line series with square markers. Plotted mean points (x, y): Treatment-naive: 310, Baseline: 290, 1M post-switch: 250, 3M post-switch: 260, 6M post-switch: 250, 12M post-switch: 235. Text above the plot: a bracket labeled asterisk asterisk spanning Baseline to 6M post-switch and a bracket labeled asterisk asterisk asterisk spanning Baseline to 12M post-switch. C) Line graph of The height of the PED across time points with vertical error bars and one bracket annotation above the plot. X-axis label: Treatment-naive, Baseline, 1M post-switch, 3M post-switch, 6M post-switch, 12M post-switch. Y-axis label: The height of the PED (micrometer). Y-axis range: 0 to 500. One line series with triangular markers. Plotted mean points (x, y): Treatment-naive: 270, Baseline: 275, 1M post-switch: 235, 3M post-switch: 210, 6M post-switch: 205, 12M post-switch: 185. Text above the plot: a bracket labeled asterisk spanning Baseline to 12M post-switch.

Changes in BCVA,CMT and PED height at different time points. (a) Mean best-corrected visual acuity (BCVA, logMAR); (b) mean central macular thickness (CMT); (c) mean pigment epithelial detachment (PED) height. Error bars represent standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001 compared with baseline after Bonferroni correction.

Following the switch to faricimab, CMT demonstrated a continuous decreasing trend. After Bonferroni correction, CMT was significantly reduced at months 6 and 12 compared with baseline, with mean decreases of 39.67 μm and 55.59 μm, respectively (adjusted P = 0.0063 and 0.0009, respectively; Figure 2b).

PED height decreased progressively following the switch to faricimab. The mean baseline PED height was 275.38 ± 150.69 μm, decreasing to 234.33 ± 147.77 μm after the first injection. After Bonferroni correction, the reductions at months 1, 3, and 6 did not reach statistical significance (adjusted P = 0.373, 0.117, and 0.129, respectively). At month 12, PED height was significantly reduced compared with baseline, with a mean decrease of 88.83 μm (adjusted P = 0.045; Figure 2c).

LMM sensitivity analyses demonstrated significant overall time effects for BCVA (P = 0.012), CMT (P < 0.001), and PED height (P = 0.002). For BCVA, the LMM identified a significant improvement at month 12 compared with baseline after Bonferroni correction (adjusted P = 0.002), whereas the primary RM-ANOVA did not demonstrate a statistically significant overall change (P = 0.065). The LMM findings for CMT and PED height were consistent with the primary RM-ANOVA results, supporting the observed anatomical improvements. Given the discrepancy between the two analytical methods, the BCVA findings should be interpreted cautiously. Detailed LMM results are presented in Supplementary Table S2.

At baseline, SRH was present in 11 of 34 eyes (32.4%), decreasing to 5 of 34 eyes (14.7%) at month 12. The median maximum SRH diameter decreased from 0.65 DD (IQR, 0.45–1.66) at baseline to 0.00 DD (IQR, 0.00–0.48) at month 12, with a significant overall difference across the five time points (Friedman test, χ2 = 39.92, P < 0.001, Table 2). Post hoc comparisons demonstrated significant reductions at months 1, 3, 6, and 12 versus baseline (all Bonferroni-adjusted P = 0.0039).

Interobserver reproducibility was assessed for manually measured SHRM height, PED height, and maximum SRH diameter. The ICCs were 0.86 (95% CI: 0.73–0.93) for SHRM height, 0.91 (95% CI: 0.82–0.96) for PED height, and 0.78 (95% CI:0.59–0.89) for maximum SRH diameter, respectively.

In addition, the prevalence of eyes with SRF and IRF before and after switching to faricimab was evaluated (Figure 3). The proportion of eyes with SRF differed significantly across the four time points (Cochran’s Q = 22.000, df = 4, P < 0.001; Figure 3a). Similarly, the overall proportion of eyes with IRF also differed significantly across the four time points (Cochran’s Q = 15.515, df = 4, P = 0.004; Figure 3b).

Figure 3.

Two bar graphs showing percentages of eyes with subretinal fluid and intraretinal fluid over time.

Changes in Retinal Fluid at different time points. (a) Percentage of eyes with subretinal fluid (SRF) after switching; (b) Percentage of eyes with intraretinal fluid (IRF) after switching. *P < 0.05 compared with baseline after Bonferroni correction.

Compared with baseline, the proportion of eyes with SRF showed a decreasing trend at months 1 and 3 after switching, but the differences did not reach statistical significance (adjusted P = 0.281 and P = 0.063, respectively). However, at months 6 and 12 after switching, the proportion of eyes with SRF was significantly lower than that at baseline (adjusted P = 0.008 and P = 0.004, respectively; Figure 3a). For SRF, the proportion of eyes with SRF decreased from 28/34 (82.4%) at baseline to 17/34 (50.0%) at month 12. Among the 28 eyes with SRF at baseline, SRF resolved in 11 eyes and persisted in 17 eyes; among these 17 eyes, the amount of fluid decreased relative to baseline in 13 eyes and worsened in 4 eyes. No new SRF developed in any of the 6 eyes without baseline SRF.

For IRF, no significant differences were observed at months 1, 3, or 6 after switching compared with baseline (Bonferroni-adjusted P = 0.875, P = 0.875, and P = 0.500, respectively). At 12 months after switching, the proportion of eyes with IRF decreased significantly compared with baseline (Bonferroni-adjusted P = 0.025; Figure 3b). The proportion of eyes with IRF decreased from 18/34 (52.9%) at baseline to 8/34 (23.5%) at month 12. Among the 18 eyes with IRF at baseline, IRF resolved in 11 eyes and persisted in 7 eyes; among these 7 eyes, the amount of fluid decreased relative to baseline in 3 eyes and worsened in 4 eyes. Among the 16 eyes without baseline IRF, 1 eye developed new IRF, while the remaining 15 eyes remained free of IRF. At month 12, 44.1% of eyes achieved a dry macula.

The changes in injection intervals before and after switching are illustrated using a paired dot plot in Figure 4. After summarizing injection intervals at the study-eye level, the median injection interval increased from 4.5 weeks before switching (interquartile range [IQR], 4.0–12.0 weeks) to 8.0 weeks after switching (IQR, 4.0–11.0 weeks). The Wilcoxon signed-rank test showed that injection intervals were significantly prolonged after switching compared with before switching (n = 34, W = 184.0, Z ≈ 2.39, P = 0.017). Overall, 18 patients (52.9%) achieved a treatment interval of ≥8 weeks, including 7 patients (20.6%) who achieved an interval of ≥12 weeks and 3 patients who achieved an interval of ≥16 weeks. The mean number of injections after switching was 5.85 ± 1.54.

Figure 4.

A paired dot plot showing injection interval in weeks before and after switching to faricimab.

Paired dot plot of injection intervals before and after switching from aflibercept to faricimab. Each dot represents the median injection interval of an individual eye (n = 34), and connecting lines indicate within-eye changes before and after switching. Injection intervals are expressed in weeks.

Secondary Outcomes: Exploratory Associations of SHRM Height Changes with Treatment Intervals and Visual Outcomes

Among the 34 eyes included in the study, 13 eyes (38.2%) exhibited SHRM at the time of switching and were included in the exploratory longitudinal analyses. These eyes received a total of 79 faricimab injections, yielding 66 longitudinal observations.

GEE analysis showed that reductions in SHRM height were significantly associated with contemporaneous prolongation of treatment intervals (B = −3.299 weeks per 100-μm increase in SHRM height; 95% CI: −4.323 to −2.275; P < 0.001). This association remained statistically significant after excluding four SHRM rebound events (B = −2.718; 95% CI: −5.257 to −0.179; P = 0.036; Table 3). However, no statistically significant association was observed between SHRM changes and concurrent changes in logMAR BCVA in either the primary GEE model (B = −0.040 per 100-μm increase in SHRM height; 95% CI: −0.107 to 0.028; P = 0.248) or the sensitivity analysis excluding rebound events (P = 0.442; Table 4).

Table 3.

GEE Model Analysis of the Association Between SHRM Height Changes and Contemporaneous Treatment-Interval Changes

Parameter Main Model (n = 66) Excluding Rebound Events (n = 62)
B (95% CI) P value B (95% CI) P value
Intercept 3.501 (1.710 to 5.291) <0.001 3.840 (1.903 to 5.777) <0.001
ΔSHRM (per 100 μm) −3.299 (−4.323 to −2.275) <0.001 −2.718 (−5.257 to −0.179) 0.036
Injection number −0.605 (−0.990 to −0.219) 0.002 −0.631 (−1.040 to −0.222) 0.003

Notes: The dependent variable was the change in treatment interval (ΔInterval, weeks). ΔSHRM and ΔInterval were calculated between consecutive observations. The ΔSHRM coefficients are expressed per 100-μm increase in SHRM height. A negative coefficient indicates that SHRM reduction is associated with contemporaneous treatment-interval prolongation. The sensitivity analysis excluded four rebound events, defined as ΔSHRM > +50 μm. An exchangeable working correlation structure was used. The 66 and 62 observations were derived from 13 independent eyes of 13 patients.

Table 4.

GEE Model Analysis of the Association Between SHRM Height Changes and Concurrent Visual Changes

Parameter Main Model (n = 66) Excluding Rebound Events (n = 62)
B (95% CI) P value B (95% CI) P value
Intercept −0.006 (−0.115 to 0.103) 0.911 0.016 (−0.114 to 0.146) 0.809
ΔSHRM (per 100 μm) −0.040 (−0.107 to 0.028) 0.248 0.049 (−0.076 to 0.173) 0.442
Injection number 0.0003 (−0.0259 to 0.0265) 0.983 0.0001 (−0.0277 to 0.0279) 0.955
Baseline logMAR −0.043 (−0.072 to −0.015) 0.003 −0.047 (−0.073 to −0.022) <0.001

Note: The dependent variable was the change in logMAR best-corrected visual acuity (ΔlogMAR). The sensitivity analysis excluded four SHRM rebound events (ΔSHRM > +50 μm). An independence working correlation structure was used for the GEE models. ΔSHRM, ΔInterval, and ΔlogMAR denote changes calculated as the value at the subsequent time point minus that at the preceding time point. Negative ΔSHRM and ΔlogMAR indicate reductions, whereas positive ΔInterval indicates injection-interval prolongation. The regression coefficients for ΔSHRM are expressed per 100-μm change in SHRM height. The reported sample sizes represent longitudinal observations derived from 13 independent eyes rather than independent observations.

Additional sensitivity analyses addressing eye-level clustering and temporal ordering are presented in Supplementary Tables S3 and S4. The temporally ordered analyses did not demonstrate a statistically significant association between SHRM changes and subsequent injection intervals.

Discussion

This retrospective real-world study demonstrated average sustained anatomical improvements and significant prolongation of observed treatment intervals 12 months after switching to faricimab among nAMD eyes with suboptimal aflibercept response. Nevertheless, complete anatomical resolution was not universal: 50.0% of eyes still had SRF, 23.5% had IRF and 14.7% had SRH at the 12-month time-point. While mean BCVA showed numerical improvement, this change failed to reach statistical significance. In the exploratory subgroup of eyes with SHRM, longitudinal reductions in SHRM height were associated with concurrent prolongation of treatment intervals. Therefore, dynamic changes in SHRM height may serve as a potential imaging biomarker to guide individualized adjustment of treatment intervals, although further validation is warranted.

Previous real-world studies in Asian populations have consistently shown that, in patients with refractory nAMD, switching to faricimab can achieve anatomical improvement, whereas visual gains are often limited or not statistically significant. In the post hoc analysis of the Asian subgroup from TENAYA/LUCERNE, the mean BCVA gain was 7.1 letters, accompanied by a CST reduction of 129.9 μm.24 Similarly, other real-world cohorts reported a mean CST reduction of 41.6 μm after switching, but without significant improvement in BCVA.8 Pandit et al reported that, after five faricimab injections in 218 eyes, the mean PED height decreased by 30 μm and the mean CST decreased by 48.2 μm, Snellen VA improved slightly from 20/76 to 20/71, although this improvement did not reach statistical significance.25 Overall, the findings of the present study are consistent with the trends reported in these previous studies. In our cohort, mean CMT decreased by 55.59 μm from baseline at 12 months, and mean PED height decreased by 88.83 μm. The proportion of eyes with SRF decreased from 82.4% to 50.0%, and the proportion of eyes with IRF also showed a marked reduction. In addition, the prevalence of SRH decreased from 32.4% at baseline to 14.7% at month 12. However, compared with randomized controlled trials such as TENAYA and LUCERNE, which mainly enrolled treatment-naïve patients, the magnitude of BCVA improvement in the present study was relatively limited. Although BCVA improved by approximately 8 ETDRS letters on average, this change did not reach statistical significance. The discrepancy may be attributable to the fact that the eyes included in the present study were chronic, refractory cases with a history of multiple prior aflibercept treatments and suboptimal responses. These eyes may have already developed irreversible damage to the RPE and photoreceptors, accompanied by disruption of the ellipsoid zone (EZ),26 resulting in limited residual retinal neural functional reserve. Consequently, even after switching to faricimab, which has a more comprehensive mechanism of action, the potential for visual acuity improvement may have been substantially constrained, leading to a dissociation between functional visual benefit and anatomical improvement.

Notably, the anatomical biomarkers assessed in this study, including CMT, PED, SRF, and IRF, exhibited distinct temporal patterns across different time points. This temporal heterogeneity suggests that different OCT biomarkers may reflect distinct pathological processes that respond differently to pharmacological treatment. Faricimab is the first bispecific antibody developed for the treatment of nAMD that simultaneously targets VEGF-A and Ang-2. The formation of SRF is associated with MNV leakage, RPE pump dysfunction, and disruption of outer blood–retinal barrier (oBRB) homeostasis, and it is generally sensitive to anti-VEGF therapy, often showing a rapid response.27 In contrast, IRF may involve impairment of the inner blood–retinal barrier (iBRB), Müller cell–related cystoid edema, or degenerative changes, and may therefore demonstrate slower or incomplete resolution.28 Through its anti–VEGF-A activity, faricimab inhibits endothelial proliferation, neovascularization, and vascular permeability, thereby reducing macular leakage and retinal fluid accumulation.16 In addition, its anti–Ang-2 activity may indirectly enhance endothelial junction stability, pericyte coverage, and blood–retinal barrier integrity, while reducing vascular sensitivity to VEGF-A and inflammatory mediators. Because Müller cells are involved in the maintenance of the blood–retinal barrier and the regulation of inflammation, attenuation of vascular leakage and inflammatory activity may facilitate the recovery of Müller cell–mediated fluid clearance.29 The CATT study showed that SRF decreased by 40.5% within 4 weeks of anti-VEGF treatment, whereas IRF decreased by only 23.3% during the same period and persisted in 48.7% of eyes at week 52. These findings are broadly consistent with the trend observed in our study.30,31 In this study, SRF showed a significant reduction at both month 6 and month 12, whereas IRF exhibited a significant decrease only at month 12, indicating that improvement in IRF was slower than that in SRF. SRH is another clinically relevant manifestation of neovascular activity in nAMD. Previous real-world studies of faricimab in previously treated nAMD have also included SRH as a clinical indicator of persistent disease activity.32 In addition, resolution of SRH following faricimab treatment has been reported in nAMD, although that study involved treatment-naïve eyes.33 Taken together, these findings suggest that changes in SRH may provide complementary clinical information regarding neovascular activity alongside other OCT-based biomarkers such as SRF and IRF. Suppression of neovascular activity may reduce further bleeding from abnormal neovascular vessels and allow existing SRH to gradually resolve.

Nevertheless, complete resolution of retinal fluid was not achieved in all eyes at month 12. Persistent retinal fluid may reflect chronic retinal structural alterations, including degenerative cystoid changes that respond poorly to anti-VEGF therapy, or ongoing exudative activity despite treatment.34,35 Furthermore, the potential influence of individualized PRN treatment intensity on incomplete fluid resolution cannot be excluded.

PED is thought to result from active leakage from choroidal neovascularization (CNV) vessels combined with relative insufficiency of the RPE pump function, which together fail to counteract the intralesional hydrostatic pressure. Faricimab may promote PED resolution through two complementary mechanisms. On the one hand, by inhibiting VEGF-A, it reduces CNV vascular permeability, decreases hydrostatic pressure within the PED, and facilitates RPE reattachment. On the other hand, by inhibiting Ang-2, it may promote CNV vascular normalization, characterized by vascular regression and increased pericyte coverage, thereby allowing the lesion to evolve from mechanical elevation toward a flatter fibrotic scar. The finding that PED reached statistical significance at month 12 may be explained by the fact that PED resolution requires structural reduction of the leakage source, together with Ang-2–mediated chronic vascular stabilization. Consequently, PED height may decrease progressively over time rather than showing an early and rapid response.

In this background, the innovative aspect of the present study lies in the exploratory subgroup analysis of SHRM, which provides a more refined imaging-based explanation for the aforementioned dissociation mechanism. Our findings demonstrated an association between reductions in SHRM height and contemporaneous prolongation of treatment intervals, whereas no significant association was observed between SHRM changes and visual acuity changes. Although a post hoc analysis of the phase III HAWK and HARRIER trials suggested that SHRM may serve as a predictive biomarker of long-term visual prognosis in patients with nAMD.36 Given the small subgroup size and the exploratory nature of these analyses, further prospective studies are warranted to clarify the clinical significance of dynamic SHRM changes.

The increase in the observed injection interval is clinically relevant as a treatment-burden outcome but should not be equated with pharmacologic durability. This finding should be interpreted in the context of the PRN treatment regimen used after switching. Under a PRN regimen, injection intervals may be influenced not only by disease activity and treatment response but also by the frequency of follow-up visits, clinician judgment, patient adherence, and appointment scheduling. Therefore, the observed interval prolongation should be interpreted cautiously and may reflect both treatment effects and real-world management factors.

In current clinical practice, treatment decisions during the maintenance phase of refractory nAMD are primarily based on BCVA and conventional OCT parameters, such as SRF, IRF, and CMT. However, in chronic patients whose visual acuity has reached a plateau, these indicators often remain relatively stable and may provide limited dynamic information for individualized adjustment of treatment intervals. Our study suggests that changes in SHRM height may serve as an important complementary parameter within this decision-making framework. It should be noted that this analysis was based on a post hoc subgroup evaluation. Given its exploratory nature and limited statistical power, these findings should be interpreted as exploratory and hypothesis-generating.

Our study has several limitations. First, its retrospective, single-center design may have introduced selection bias. As this was a retrospective study without a control group continuing aflibercept, natural fluctuations in disease activity and regression to the mean may have contributed to the observed changes. Second, under the PRN regimen, injection intervals are affected not only by disease activity and therapeutic response but also by follow-up frequency, clinical decision-making, patient adherence and appointment arrangement; thus, the prolonged injection intervals should be interpreted with caution. Furthermore, the association between SHRM dynamics and treatment intervals may be confounded by concurrent fluctuations in other markers of disease activity. Given the limited sample size of the SHRM subgroup (13 eyes), multivariable adjustment was not performed to avoid over parameterization and unstable estimates. Future prospective studies with larger sample sizes, potentially incorporating OCTA flow signals and AI-assisted SHRM segmentation, may help further validate our findings.

Conclusions

In summary, switching to faricimab was associated with overall anatomical improvements and prolonged treatment intervals among pretreated nAMD eyes, while visual gains remained limited. However, complete anatomical resolution was not achieved in all patients. Importantly, given the PRN treatment strategy, the observed prolongation of injection intervals may also be influenced by visit scheduling and physician discretion and should not be interpreted as a direct measure of pharmacological durability. In the exploratory subgroup of eyes with SHRM, longitudinal reductions in SHRM height were associated with contemporaneous prolongation of treatment intervals, but not with concurrent changes in visual acuity. These findings suggest that dynamic changes in SHRM height may represent an exploratory imaging feature associated with treatment interval changes; however, its prospective predictive value and clinical utility remain to be validated.

Acknowledgments

The authors thank the clinical staff of the Department of Ophthalmology, Shandong Provincial Hospital, for their support in data collection and patient management.

Data Sharing Statement

The datasets generated and/or analyzed during the current study are not publicly available because they contain clinical information from hospital medical records, but are available from the corresponding author on reasonable request and with permission from Shandong Provincial Hospital.

Ethics Approval

This retrospective observational study was reviewed and approved by the Ethics Committee for Biomedical Research Involving Human Subjects of Shandong Provincial Hospital, ethical approval SWYX:NO.2025-156. The study was conducted in accordance with the tenets of the Declaration of Helsinki and relevant institutional guidelines.

Consent for Publication

Appropriate publication consent has been obtained for all images, videos and audio materials. Relevant participants have reviewed the manuscript.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declare that they have no competing interests.

References

  • 1.Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration. Lancet. 2018;392(10153):1147–13. doi: 10.1016/S0140-6736(18)31550-2 [DOI] [PubMed] [Google Scholar]
  • 2.Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis. 2016;3:34. doi: 10.1186/s40662-016-0063-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Song P, Du Y, Chan KY, et al. The national and subnational prevalence and burden of age-related macular degeneration in China. J Glob Health. 2017;7(2):020703. doi: 10.7189/jogh.07.020703 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Malhotra K, Colcombe J, Patil S, et al. U.S. trends of anti-vascular endothelial growth factor use from 2017–2023: an analysis of medicare, medicaid, and commercial insurance. PLoS One. 2026;21(1):e0335390. doi: 10.1371/journal.pone.0335390 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ciombor KK, Berlin J. Aflibercept—a decoy VEGF receptor. Curr Oncol Rep. 2014;16(2):368. doi: 10.1007/s11912-013-0368-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sharma D, Zachary I, Jia H, et al. Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. Invest Ophthalmol Vis Sci. 2023;64(5):28. doi: 10.1167/iovs.64.5.28 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tan CS, Ngo WK, Chay IW, et al. Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options. Clin Ophthalmol. 2022;16:917–933. doi: 10.2147/opth.S231913 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Neo EZO, Liang KWO, Toh ZH, et al. Real world outcomes of faricimab in treatment resistant neovascular age-related macular degeneration among Asian patients. Sci Rep. 2025;15(1):33672. doi: 10.1038/s41598-025-18376-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Shirley M. Faricimab: first approval. Drugs. 2022;82(7):825–830. doi: 10.1007/s40265-022-01713-3 [DOI] [PubMed] [Google Scholar]
  • 10.US FDA. VABYSMO™ (faricimab-svoa) injection, for intravitreal use - US prescribing information. 2022. Available from: https://www.fda.gov. Accessed 4, Mar 2022.
  • 11.Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, Phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi: 10.1016/S0140-6736(22)00010-1 [DOI] [PubMed] [Google Scholar]
  • 12.Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741–755. doi: 10.1016/S0140-6736(22)00018-6 [DOI] [PubMed] [Google Scholar]
  • 13.Raimondi R, Felfeli T, Bogdanova-Bennet A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8(6):537–544. doi: 10.1016/j.oret.2023.11.015 [DOI] [PubMed] [Google Scholar]
  • 14.Kataoka K, Itagaki K, Hashiya N, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(1):43–51. doi: 10.1007/s00417-023-06222-x [DOI] [PubMed] [Google Scholar]
  • 15.Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041–4046. doi: 10.2147/opth.S395279 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hafner M, Asani B, Eckardt F, et al. Deep-learning-assisted analysis of early biomarker changes in treatment-naïve patients with neovascular AMD under intravitreal faricimab. Ophthalmol Ther. 2025;14(5):1025–1037. doi: 10.1007/s40123-025-01125-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Willoughby AS, Ying G-S, Toth CA, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(9):1846–1853.e5. doi: 10.1016/j.ophtha.2015.05.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pokroy R, Mimouni M, Barayev E, et al. Prognostic value of subretinal hyperreflective material in neovascular age-related macular degeneration treated with bevacizumab. Retina. 2018;38(8):1485–1491. doi: 10.1097/iae.0000000000001748 [DOI] [PubMed] [Google Scholar]
  • 19.Sil Kar S, Cetin H, Lunasco L, et al. OCT-derived radiomic features predict anti-VEGF response and durability in neovascular age-related macular degeneration. Ophthalmol Sci. 2022;2(4):100171. doi: 10.1016/j.xops.2022.100171 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Fang M, Chanwimol K, Maram J, et al. Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. Br J Ophthalmol. 2023;107(3):399–405. doi: 10.1136/bjophthalmol-2021-319602 [DOI] [PubMed] [Google Scholar]
  • 21.Moraes G, Struyven R, Wagner SK, et al. Quantifying changes on OCT in eyes receiving treatment for neovascular age-related macular degeneration. Ophthalmol Sci. 2024;4(6):100570. doi: 10.1016/j.xops.2024.100570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kawashima Y, Hata M, Oishi A, et al. Association of vascular versus avascular subretinal hyperreflective material with aflibercept response in age-related macular degeneration. Am J Ophthalmol. 2017;181:61–70. doi: 10.1016/j.ajo.2017.06.015 [DOI] [PubMed] [Google Scholar]
  • 23.Kodjikian L, Parravano M, Clemens A, et al. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. Eye. 2021;35(8):2119–2135. doi: 10.1038/s41433-021-01487-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Takahashi K, Cheung CMG, Iida T, et al. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch Clin Exp Ophthalmol. 2023;261(11):3125–3137. doi: 10.1007/s00417-023-06071-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pandit SA, Momenaei B, Wakabayashi T, et al. Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8(4):360–366. doi: 10.1016/j.oret.2023.10.018 [DOI] [PubMed] [Google Scholar]
  • 26.Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9(1):62–79. doi: 10.1016/j.gendis.2021.02.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Gigon A, Iskandar A, Kasser S, et al. Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration. Eye. 2024;38(7):1342–1348. doi: 10.1038/s41433-023-02900-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gianniou C, Dirani A, Jang L, et al. Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranibizumab: functional and structural outcome. Retina. 2015;35(6):1195–1201. doi: 10.1097/iae.0000000000000465 [DOI] [PubMed] [Google Scholar]
  • 29.Joussen AM, Ricci F, Paris LP, et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35(5):1305–1316. doi: 10.1038/s41433-020-01377-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Jaffe GJ, Ying GS, Toth CA, et al. Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2019;126(2):252–260. doi: 10.1016/j.ophtha.2018.08.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Jaffe GJ, Martin DF, Toth CA, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120(9):1860–1870. doi: 10.1016/j.ophtha.2013.01.073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kucharczuk J, Kasprzak H, Gawęcki M. Switching from aflibercept to faricimab in the treatment of neovascular age-related macular degeneration: short-term results from real-life study. J Clin Med. 2025;14(20):7345. doi: 10.3390/jcm14207345 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sivachandran N, Ji PX, Khan H, et al. Visual and anatomic outcomes of faricimab in naïve neovascular age-related macular degeneration with subretinal hemorrhage: a multi-centre retrospective analysis. Clin Ophthalmol. 2026;20:589703. doi: 10.2147/OPTH.S589703 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Foss AJE, Almeida D, Cheung CMG, Ogura Y, de Cock E, Empeslidis T. To treat or not to treat? Resolving the question of subretinal and intraretinal fluid in age-related macular degeneration: a narrative review. Ophthalmol Ther. 2025;14(3):489–514. doi: 10.1007/s40123-025-01093-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Mettu PS, Allingham MJ, Cousins SW. Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82:100906. doi: 10.1016/j.preteyeres.2020.100906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sadda S, Sarraf D, Khanani AM, et al. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER. Br J Ophthalmol. 2024;108(6):852–858. doi: 10.1136/bjo-2023-323577 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets generated and/or analyzed during the current study are not publicly available because they contain clinical information from hospital medical records, but are available from the corresponding author on reasonable request and with permission from Shandong Provincial Hospital.


Articles from Drug Design, Development and Therapy are provided here courtesy of Dove Press

RESOURCES